未经证实:对于不可切除的肝内患者,没有治愈性治疗选择,胆管癌(IHC)。这项研究的目的是评估使用Y90标记的玻璃微球的患者进行放射节段切除术/肺叶切除术的疗效;不可切除的IHC。
未经批准:此IRB批准,包括单中心研究,16例(年龄:67±7.7岁)进行IHC的患者接受了放射节段切除术或肺叶切除术,2009年5月至2019年10月期间使用Y90标记的玻璃微球进行治疗。辐射,肺段切除术/肺叶切除术定义为至少190Gy剂量进入治疗的肝脏;体积。
UASSIGNED:IHC诊断的中位OS为22.7个月(95%CI:13.9-66.1),放射栓塞治疗时间为7个月(95%CI:4.33-54.17)。没有接受治疗的患者,放疗栓塞前的化疗中位OS明显更长(26.8vs.5.9个月,P=0.03)。4例患者放疗栓塞后生存期>20个月,其中2例患者生存期为42个月和54个月。没有30天的死亡率,也没有严重的死亡率,并发症。
UNASSIGNED:放射性肺段切除术/肺叶切除术是安全的,副作用最小。中位数,研究组的操作系统是适度的;然而,4例患者(25%)表现出优异的生存率。这些结果表明,需要进行更大的研究来定义IHC患者组,大多数受益于这个程序。
UNASSIGNED: There is no curative treatment option for patients with unresectable intrahepatic, cholangiocarcinoma (IHC). The aim of this study was to evaluate the efficacy of; radiation segmentectomy/lobectomy using Y90-labeled glass microspheres in patients with; unresectable IHC.
UNASSIGNED: This IRB-approved, single-center study included, 16 patients (age: 67 ± 7.7 years) with IHC who received radiation segmentectomy or lobectomy, treatment using Y90-labeled glass microspheres between May 2009 and October 2019. Radiation, segmentectomy/lobectomy was defined as at least 190 Gy dose delivered into treated liver; volume.
UNASSIGNED: The median OS from IHC diagnosis was 22.7 months (95% CI: 13.9-66.1) and from, radioembolization it was 7 months (95% CI: 4.33-54.17). Patients who did not receive, chemotherapy before the radioembolization had significantly longer median OS (26.8 vs. 5.9, months, P = 0.03). Four patients had >20 months survival after radioembolization, including 2, patients with survival of 42 and 54 months. There was no 30-day mortality and no severe, complications.
UNASSIGNED: Radiation segmentectomy/lobectomy is safe with minimal side effects. The median, OS of the study group is modest; however, 4 patients (25%) showed excellent survival. These results suggest a need for a larger study to define the IHC patient group who could, most benefit from this procedure.